{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:31:56Z","timestamp":1759530716924},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011102","name":"European Union 7th Framework Programme","doi-asserted-by":"crossref","award":["222741-METOXIA"],"award-info":[{"award-number":["222741-METOXIA"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"crossref","award":["2010014","2012002"],"award-info":[{"award-number":["2010014","2012002"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008730","name":"Norwegian Cancer Society","doi-asserted-by":"crossref","award":["2006183"],"award-info":[{"award-number":["2006183"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012446","name":"Akershus University Hospital","doi-asserted-by":"crossref","award":["2010003"],"award-info":[{"award-number":["2010003"]}],"id":[{"id":"10.13039\/501100012446","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.critrevonc.2015.01.003","type":"journal-article","created":{"date-parts":[[2015,1,13]],"date-time":"2015-01-13T02:52:09Z","timestamp":1421117529000},"page":"114-124","source":"Crossref","is-referenced-by-count":15,"title":["Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: Opportunities for signaling-adapted therapies"],"prefix":"10.1016","volume":"95","author":[{"given":"Anne Hansen","family":"Ree","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjersti","family":"Flatmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Gr\u00f8n","family":"Saelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigurd","family":"Folkvord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svein","family":"Dueland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrine R\u00f8e","family":"Redalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2015.01.003_bib0330","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0335","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.radonc.2008.05.022","article-title":"Evidence and research in rectal cancer","volume":"87","author":"Valentini","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0340","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0345","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1200\/JCO.2012.42.8771","article-title":"Clinical outcome of the ACCORD 12\/0405 PRODIGE 2 randomized trial in rectal cancer","volume":"30","author":"Gerard","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0350","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(13)70599-0","article-title":"Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study","volume":"15","author":"Bosset","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0355","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2010.01.008","article-title":"Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer","volume":"138","author":"Rahbari","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0360","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/bjc.2011.97","article-title":"Disseminated tumour cells as a prognostic biomarker in colorectal cancer","volume":"104","author":"Flatmark","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0365","first-page":"CD004078","article-title":"Postoperative adjuvant chemotherapy in rectal cancer operated for cure","volume":"3","author":"Petersen","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0370","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrclinonc.2011.118","article-title":"The current landscape of locally advanced rectal cancer","volume":"8","author":"Aklilu","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0375","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/SLA.0b013e3182456aa2","article-title":"Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)","volume":"255","author":"Sorbye","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0380","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1245\/s10434-012-2726-3","article-title":"Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis","volume":"20","author":"Gonzalez","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0385","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1245\/s10434-009-0487-4","article-title":"A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin","volume":"16","author":"Cao","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0390","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1586\/erm.12.46","article-title":"How many molecular subtypes? Implications of the unique tumor principle in personalized medicine","volume":"12","author":"Ogino","year":"2012","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0395","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrc3261","article-title":"Intra-tumour heterogeneity: a looking glass for cancer?","volume":"12","author":"Marusyk","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0400","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature04871","article-title":"Hypoxia signalling in cancer and approaches to enforce tumour regression","volume":"441","author":"Pouyss\u00e9gur","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0405","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nrc2540","article-title":"The impact of O2 availability on human cancer","volume":"8","author":"Bertout","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0410","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/onc.2013.121","article-title":"Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment","volume":"33","author":"Casazza","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0415","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc3007","article-title":"Strategies to improve radiotherapy with targeted drugs","volume":"11","author":"Begg","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0420","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1158\/0008-5472.CAN-11-1182","article-title":"Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer","volume":"71","author":"Toustrup","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0425","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1582-4934.2009.00944.x","article-title":"Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis","volume":"14","author":"Jubb","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0430","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1158\/1078-0432.CCR-10-1360","article-title":"Hypoxia and hypoxia-inducible factors: master regulators of metastasis","volume":"16","author":"Lu","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0435","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nrc2501","article-title":"Hypoxia signalling through mTOR and the unfolded protein response in cancer","volume":"8","author":"Wouters","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0440","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0445","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0450","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2217\/fon.12.185","article-title":"Molecular targets and mechanisms of radiosensitization using DNA damage response pathways","volume":"9","author":"Raleigh","year":"2013","journal-title":"Future Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0455","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2013.06.007","article-title":"Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience","volume":"108","author":"Ree","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0460","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1158\/2159-8290.CD-13-0337","article-title":"Improving the efficacy of chemoradiation with targeted agents","volume":"4","author":"Morgan","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0465","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0470","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI44145","article-title":"Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy","volume":"121","author":"Wander","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0475","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11523-011-0173-x","article-title":"Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences","volume":"6","author":"Cam","year":"2011","journal-title":"Target Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0480","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ejca.2010.01.001","article-title":"Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation","volume":"46","author":"Alymani","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0485","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrclinonc.2011.164","article-title":"Targeted therapies: how personal should we go?","volume":"9","author":"Martini","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0490","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1007\/s00216-010-3784-7","article-title":"Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods","volume":"397","author":"Piersma","year":"2010","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0495","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1002\/pmic.201100296","article-title":"Peptide arrays for kinome analysis: new opportunities and remaining challenges","volume":"11","author":"Arsenault","year":"2011","journal-title":"Proteomics"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0500","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.critrevonc.2011.05.002","article-title":"Optimizing targeted cancer therapy: towards clinical application of systems biology approaches","volume":"82","author":"Sikkema","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0505","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12033-011-9402-x","article-title":"Deciphering enzyme function using peptide arrays","volume":"49","author":"Thiele","year":"2011","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0510","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijrobp.2010.04.036","article-title":"Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling","volume":"78","author":"Folkvord","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0515","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10456-011-9231-3","article-title":"Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination","volume":"14","author":"Saelen","year":"2011","journal-title":"Angiogenesis"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0520","doi-asserted-by":"crossref","first-page":"e50806","DOI":"10.1371\/journal.pone.0050806","article-title":"Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer","volume":"7","author":"Ree","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0525","doi-asserted-by":"crossref","first-page":"e63723","DOI":"10.1371\/journal.pone.0063723","article-title":"Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer","volume":"8","author":"R\u00f8e","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0530","doi-asserted-by":"crossref","first-page":"e72692","DOI":"10.1371\/journal.pone.0072692","article-title":"Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma","volume":"8","author":"Tahiri","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0535","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0540","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/bmj.38937.646400.55","article-title":"Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study","volume":"333","author":"MERCURY Study Group","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0545","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/cncr.10327","article-title":"Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy","volume":"94","author":"Bouzourene","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0550","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2013.03.017","article-title":"Magnetic resonance-guided histopathology for improved accuracy of tumor response evaluation of neoadjuvant treatment in organ-infiltrating rectal cancer","volume":"107","author":"Hole","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0555","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S1470-2045(08)70073-1","article-title":"Activation of the PI3-K\/AKT pathway and implications for radioresistance mechanisms in head and neck cancer","volume":"9","author":"Bussink","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2014.04.010","article-title":"Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines","author":"Anderson","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0565","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0570","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.radonc.2013.03.023","article-title":"Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer","volume":"107","author":"Buijsen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0575","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00109-007-0258-2","article-title":"Pericytes: gatekeepers in tumour cell metastasis?","volume":"86","author":"Gerhardt","year":"2008","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0580","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ajh.21745","article-title":"Pericytes and vessel maturation during tumor angiogenesis and metastasis","volume":"85","author":"Raza","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0585","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrclinonc.2011.83","article-title":"Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?","volume":"8","author":"De Bock","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0590","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2537","article-title":"Tumor angiogenesis: molecular pathways and therapeutic targets","volume":"17","author":"Weis","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0595","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000087840","article-title":"Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients","volume":"69","author":"Yonenaga","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0600","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.11.024","article-title":"Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway","volume":"21","author":"Cooke","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0605","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2010.30.0855","article-title":"Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08","volume":"29","author":"Allegra","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0610","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","article-title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial","volume":"13","author":"de Gramont","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0615","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2012.44.4711","article-title":"Bevacizumab in stage II\u2013III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial","volume":"31","author":"Allegra","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0620","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0625","first-page":"CD008368","article-title":"Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer","volume":"12","author":"McCarthy","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0630","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1158\/1078-0432.CCR-09-2283","article-title":"New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways","volume":"16","author":"Dasari","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0635","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1158\/1078-0432.CCR-13-0027","article-title":"Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens","volume":"19","author":"Ng","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0640","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","article-title":"Picking the point of inhibition: a comparative review of PI3K\/AKT\/mTOR pathway inhibitors","author":"Dienstmann","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0645","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1200\/JCO.2014.57.3865","article-title":"Enhancing the efficacy of radiation therapy: premises, promises, and practicality","volume":"32","author":"Coleman","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.01.003_bib0650","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10585-009-9248-9","article-title":"Osteoblast-induced EGFR\/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling","volume":"26","author":"Bratland","year":"2009","journal-title":"Clin Exp Metastasis"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T20:53:56Z","timestamp":1589489636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1040842815000049"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.01.003","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}